​

Anixa Biosciences (ANIX) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

ANIX Stock Forecast

Anixa Biosciences (ANIX) stock forecast, based on 6 Wall Street analysts, predicts a 12-month average price target of $5.83, with a high of $10.00 and a low of $3.50. This represents a 37.50% increase from the last price of $4.24.

$2 $3 $4 $5 $6 $7 $8 $9 $10 High: $10 Avg: $5.83 Low: $3.5 Last Closed Price: $4.24

ANIX Stock Rating

Anixa Biosciences stock's rating consensus is Buy, based on 6 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 6 0 6 Strong Sell Sell Hold Buy Strong Buy

ANIX Price Target Upside V Benchmarks

TypeNameUpside
StockAnixa Biosciences37.50%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$10.00
Last Closing Price$4.24$4.24$4.24
Upside/Downside--135.85%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 2522---4
Sep, 2521---3
Aug, 2521---3
Jul, 2521---3
Jun, 2521---3
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 21, 2025Maxim Group$10.00$3.16216.46%135.85%
Sep 17, 2024Yi ChenH.C. Wainwright$3.50$1.72103.49%-17.45%
Dec 23, 2022Matthew BarcusChardan Capital$4.00$1.91109.42%-5.66%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 17, 2024H.C. WainwrightBuyBuyhold
Aug 07, 2024EF HuttonBuyinitialise
Jun 10, 2024H.C. WainwrightBuyBuyhold
Dec 23, 2022Chardan CapitalBuyinitialise

Financial Forecast

EPS Forecast

Oct 21 Oct 23 Oct 24 Oct 25 Oct 26 Oct 27 Oct 28 Oct 29
Oct 21Oct 23Oct 24Oct 25Oct 26Oct 27Oct 28Oct 29
Reported$-0.45$-0.32$-0.39-----
Avg Forecast$-0.41$-0.32$-0.40$-0.37$-0.24$-0.24$-0.25$0.05
High Forecast$-0.41$-0.32$-0.40$-0.37$-0.24$-0.24$-0.25$0.05
Low Forecast$-0.41$-0.32$-0.40$-0.37$-0.24$-0.24$-0.25$0.05
Surprise %9.76%--2.50%-----

Revenue Forecast

$0 $30M $60M $90M $120M $150M Oct 21 Oct 23 Oct 24 Oct 25 Oct 26 Oct 27 Oct 28 Oct 29
Oct 21Oct 23Oct 24Oct 25Oct 26Oct 27Oct 28Oct 29
Reported$512.50K$210.00K------
Avg Forecast$500.00K$200.00K$150.00M$120.00M-$34.00M-$22.60M
High Forecast$500.00K$200.00K$150.00M$120.00M-$34.00M-$22.60M
Low Forecast$500.00K$200.00K$150.00M$120.00M-$34.00M-$22.60M
Surprise %2.50%5.00%------

Net Income Forecast

$-15M $-11M $-7M $-3M $1M $5M Oct 21 Oct 23 Oct 24 Oct 25 Oct 26 Oct 27 Oct 28 Oct 29
Oct 21Oct 23Oct 24Oct 25Oct 26Oct 27Oct 28Oct 29
Reported$-12.95M$-9.81M$-12.55M-----
Avg Forecast$-12.70M$-10.21M$-12.60M$-11.64M$-7.66M$-7.66M$-7.97M$1.59M
High Forecast$-12.70M$-10.21M$-12.60M$-11.64M$-7.66M$-7.66M$-7.97M$1.59M
Low Forecast$-12.70M$-10.21M$-12.60M$-11.64M$-7.66M$-7.66M$-7.97M$1.59M
Surprise %1.93%-3.88%-0.36%-----

ANIX Forecast FAQ

Is Anixa Biosciences stock a buy?

Anixa Biosciences stock has a consensus rating of Buy, based on 6 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Anixa Biosciences is a favorable investment for most analysts.

What is Anixa Biosciences's price target?

Anixa Biosciences's price target, set by 6 Wall Street analysts, averages $5.83 over the next 12 months. The price target range spans from $3.5 at the low end to $10 at the high end, suggesting a potential 37.50% change from the previous closing price of $4.24.

How does Anixa Biosciences stock forecast compare to its benchmarks?

Anixa Biosciences's stock forecast shows a 37.50% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Anixa Biosciences over the past three months?

  • October 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 66.67% Strong Buy, 33.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 66.67% Strong Buy, 33.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Anixa Biosciences’s EPS forecast?

Anixa Biosciences's average annual EPS forecast for its fiscal year ending in October 2025 is $-0.37, marking a -5.13% decrease from the reported $-0.39 in 2024. Estimates for the following years are $-0.24 in 2026, $-0.24 in 2027, $-0.25 in 2028, and $0.05 in 2029.

What is Anixa Biosciences’s revenue forecast?

Anixa Biosciences's average annual revenue forecast for its fiscal year ending in October 2025 is $120M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $0, followed by $34M for 2027, $0 for 2028, and $22.6M for 2029.

What is Anixa Biosciences’s net income forecast?

Anixa Biosciences's net income forecast for the fiscal year ending in October 2025 stands at $-11.643M, representing a -7.26% decrease from the reported $-12.554M in 2024. Projections indicate $-7.656M in 2026, $-7.656M in 2027, $-7.974M in 2028, and $1.59M in 2029.